208 related articles for article (PubMed ID: 30951590)
21. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Friedberg JW; Sharman J; Sweetenham J; Johnston PB; Vose JM; Lacasce A; Schaefer-Cutillo J; De Vos S; Sinha R; Leonard JP; Cripe LD; Gregory SA; Sterba MP; Lowe AM; Levy R; Shipp MA
Blood; 2010 Apr; 115(13):2578-85. PubMed ID: 19965662
[TBL] [Abstract][Full Text] [Related]
22. Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program.
Bussel JB; Arnold DM; Boxer MA; Cooper N; Mayer J; Zayed H; Tong S; Duliege AM
Am J Hematol; 2019 May; 94(5):546-553. PubMed ID: 30784097
[TBL] [Abstract][Full Text] [Related]
23. A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease.
Lin C; DiCioccio RA; Haykal T; McManigle WC; Li Z; Anand SM; Poe JC; Bracken SJ; Jia W; Alyea EP; Cardones AR; Choi T; Gasparetto C; Grunwald MR; Hennig T; Kang Y; Long GD; Lopez R; Martin M; Minor KK; Quinones VLP; Sung AD; Wiggins K; Chao NJ; Horwitz ME; Rizzieri DA; Sarantopoulos S
Transplant Cell Ther; 2023 Mar; 29(3):179.e1-179.e10. PubMed ID: 36577483
[TBL] [Abstract][Full Text] [Related]
24. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Flinn IW; Bartlett NL; Blum KA; Ardeshna KM; LaCasce AS; Flowers CR; Shustov AR; Thress KS; Mitchell P; Zheng F; Skolnik JM; Friedberg JW
Eur J Cancer; 2016 Feb; 54():11-17. PubMed ID: 26707592
[TBL] [Abstract][Full Text] [Related]
25. Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?
Scott IC; Scott DL
Drugs; 2014 Mar; 74(4):415-22. PubMed ID: 24610702
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies.
Baluom M; Grossbard EB; Mant T; Lau DT
Br J Clin Pharmacol; 2013 Jul; 76(1):78-88. PubMed ID: 23190017
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic options for adult patients with previously treated immune thrombocytopenia - a systematic review and network meta-analysis.
Yang R; Lin L; Yao H; Ji O; Shen Q
Hematology; 2019 Dec; 24(1):290-299. PubMed ID: 30661482
[TBL] [Abstract][Full Text] [Related]
28. Avatrombopag Effectively Maintained Platelet Counts in a Patient with Immune Thrombocytopenia Who Was Intolerant to Tyrosine Kinase Inhibitor Therapy.
Maitland HS
Am J Case Rep; 2021 Dec; 22():e933788. PubMed ID: 34862358
[TBL] [Abstract][Full Text] [Related]
29. The status of fostamatinib in the treatment of rheumatoid arthritis.
Morales-Torres J
Expert Rev Clin Immunol; 2012 Sep; 8(7):609-15. PubMed ID: 23078058
[TBL] [Abstract][Full Text] [Related]
30. Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406.
Matsukane R; Suetsugu K; Hirota T; Ieiri I
Clin Pharmacokinet; 2022 Jul; 61(7):955-972. PubMed ID: 35781630
[TBL] [Abstract][Full Text] [Related]
31. Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies.
Martin P; Gillen M; Millson D; Oliver S; Brealey C; Grossbard EB; Baluom M; Lau D; Sweeny D; Mant T; Craven K
Drugs R D; 2016 Mar; 16(1):81-92. PubMed ID: 26739683
[TBL] [Abstract][Full Text] [Related]
32. Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials.
Kunwar S; Devkota AR; Ghimire DK
Rheumatol Int; 2016 Aug; 36(8):1077-87. PubMed ID: 27113955
[TBL] [Abstract][Full Text] [Related]
33. Current and emerging treatments based on novel mechanisms for immune thrombocytopenia.
Zeng Q; Zhang X
Sci China Life Sci; 2020 Oct; 63(10):1597-1599. PubMed ID: 32789725
[No Abstract] [Full Text] [Related]
34. Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA.
McKeage K; Lyseng-Williamson KA
Drugs Ther Perspect; 2018; 34(10):451-456. PubMed ID: 30459507
[TBL] [Abstract][Full Text] [Related]
35. Romiplostim in chronic immune thrombocytopenic purpura.
Cersosimo RJ
Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
[TBL] [Abstract][Full Text] [Related]
36. Fostamatinib (Tavalisse) for ITP.
Med Lett Drugs Ther; 2019 Feb; 61(1566):28-30. PubMed ID: 30845102
[No Abstract] [Full Text] [Related]
37. Role of the Spleen Tyrosine Kinase Pathway in Driving Inflammation in IgA Nephropathy.
McAdoo S; Tam FWK
Semin Nephrol; 2018 Sep; 38(5):496-503. PubMed ID: 30177021
[TBL] [Abstract][Full Text] [Related]
38. Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia.
Newland A; McDonald V
Immunotherapy; 2020 Dec; 12(18):1325-1340. PubMed ID: 33023353
[TBL] [Abstract][Full Text] [Related]
39. Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk.
Mehta AR; Kefela A; Toste C; Sweet D
Acta Haematol; 2022; 145(2):221-228. PubMed ID: 34913873
[TBL] [Abstract][Full Text] [Related]
40. Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial.
Weinblatt ME; Kavanaugh A; Genovese MC; Jones DA; Musser TK; Grossbard EB; Magilavy DB
J Rheumatol; 2013 Apr; 40(4):369-78. PubMed ID: 23378467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]